Genmab A/S (GMAB) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Travere Therapeutics (TVTX) has outperformed Genmab A/S (GMAB) over the past year, gaining 98.6% versus a gain of 10.1%. Over five years, TVTX leads with a +112.4% price change compared with -18.9% for GMAB. Genmab A/S is the larger company by market cap ($22.60 billion vs $4.93 billion), about 4.6 times the size, while Travere Therapeutics is growing revenue faster (+110.5% vs +19.2%).
On valuation, Travere Therapeutics trades at a lower forward P/E (9.3x vs 24.1x for Genmab A/S). Genmab A/S converts more of its revenue into profit, with a net margin of 25.9% versus -5.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMAB | TVTX |
|---|---|---|
| Share price | $36.75 | $52.34 |
| Market cap | $22.60B | $4.93B |
| 1-day change | +1.94% | +0.58% |
| YTD return | +17.05% | +36.19% |
| 1-year return | +10.11% | +98.63% |
| 5-year return | -18.86% | +112.41% |
| P/E ratio (TTM) | 28.94 | — |
| Forward P/E | 24.10 | 9.28 |
| EPS (TTM) | $1.27 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.72B | $490.73M |
| Revenue growth (YoY) | +19.19% | +110.45% |
| Net income (latest FY) | $963.00M | $-25.55M |
| Gross margin | 93.60% | 97.89% |
| Operating margin | 28.63% | -12.80% |
| Net margin | 25.89% | -5.21% |
| 52-week high | $40.17 | $68.73 |
| 52-week low | $23.62 | $22.59 |
| Distance from 52-week high | -8.51% | -23.85% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +17.61% | +43.70% |
| Average volume | 2.83M | 1.59M |
| Shares outstanding | 614.90M | 94.26M |
| Employees | 3,119 | 497 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Genmab A/S is about 4.6 times larger than Travere Therapeutics by market value ($22.60B vs $4.93B).
- TVTX has outperformed GMAB by 88.5 percentage points over the past year.
- Genmab A/S is more profitable, keeping 25.9 cents of every revenue dollar as net income versus -5.2 cents for Travere Therapeutics.
- Travere Therapeutics grew revenue faster in its latest fiscal year (+110.45% vs +19.19%).
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees
GMAB vs TVTX FAQ
Which is bigger, Genmab A/S or Travere Therapeutics?
Genmab A/S (GMAB) is larger, with a market capitalization of $22.60B compared with $4.93B for Travere Therapeutics (TVTX).
Which stock has performed better over the past year, GMAB or TVTX?
TVTX returned +98.63% over the past 12 months, compared with +10.11% for GMAB (price return, excluding dividends). Past performance does not predict future results.
Are Genmab A/S and Travere Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.